Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut, 60 (2011), pp. 1109-1116 Cross...
Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 M...
参考资料: 1.Qi X, Li J, Caussy C, et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024 May 8. doi: 10.1097/HEP.0000000000000913. Epub ahead of print. 2.European Association for the Study...
[7]Europe Medicines Agency. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex. Accessed July 2023 [8]Bazinet M, Pântea V, Cebotarescu V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interfe...
Yeo, B. Hajarizadeh, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis Hepatology, 76 (2022), pp. 139-154, 10.1002/hep.32341 Google Scholar [73] G. Cabibbo, C. Celsa, V. Calvaruso, et al. Direct acting antivirals after ...
[5] Terrault NA, Lok AS, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018, https://doi.org/10.1002/hep.29800. [6] Harry L.A. Janssen, et al. EASL 2021. PO-2395. ...
enced by the IL28B genotype, and is associated with chronic hep- atitis of a variable degree and with variable rates of fibrosis progression. Only exceptionally does infection clear spontane- ously in the chronic stage. Chronic hepatitis C proceeds towards ...
[7]Europe Medicines Agency. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex. Accessed July 2023 [8]Bazinet M, Pântea V, Cebotarescu V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interfe...
So now, moving on to the actual new hep B guidelines. So we started out by defining what are the topics, what are the really important topics and questions. So the first is on expanding treatment eligibility, the viral load threshold, the April score for determining fibrosis using antiviral...
[5] Terrault NA, Lok AS, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018, https://doi.org/10.1002/hep.29800. [6] Harry L.A. Janssen, et al. EASL 2021. PO-2395. ...